Free Trial
NASDAQ:IRMD

Iradimed (IRMD) Stock Price, News & Analysis

Iradimed logo
$58.16 +0.02 (+0.03%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Iradimed Stock (NASDAQ:IRMD)

Key Stats

Today's Range
$57.15
â–Ľ
$58.25
50-Day Range
$48.67
â–Ľ
$58.14
52-Week Range
$41.69
â–Ľ
$63.29
Volume
29,104 shs
Average Volume
42,866 shs
Market Capitalization
$739.50 million
P/E Ratio
38.78
Dividend Yield
1.17%
Price Target
$72.00
Consensus Rating
Buy

Company Overview

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Iradimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

IRMD MarketRank™: 

Iradimed scored higher than 94% of companies evaluated by MarketBeat, and ranked 20th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Iradimed has received no research coverage in the past 90 days.

  • Read more about Iradimed's stock forecast and price target.
  • Earnings Growth

    Earnings for Iradimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iradimed is 38.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.44.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iradimed is 38.74, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.00.

  • Price to Book Value per Share Ratio

    Iradimed has a P/B Ratio of 10.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Iradimed's valuation and earnings.
  • Percentage of Shares Shorted

    2.45% of the float of Iradimed has been sold short.
  • Short Interest Ratio / Days to Cover

    Iradimed has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Iradimed has recently decreased by 0.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    Iradimed pays a meaningful dividend of 1.33%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Iradimed has only been increasing its dividend for 1 years.

  • Dividend Coverage

    The dividend payout ratio of Iradimed is 43.87%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Iradimed will have a dividend payout ratio of 34.00% next year. This indicates that Iradimed will be able to sustain or increase its dividend.

  • Read more about Iradimed's dividend.
  • Percentage of Shares Shorted

    2.45% of the float of Iradimed has been sold short.
  • Short Interest Ratio / Days to Cover

    Iradimed has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Iradimed has recently decreased by 0.91%, indicating that investor sentiment is improving.
  • News Sentiment

    Iradimed has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Iradimed this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for IRMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Iradimed to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iradimed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.80% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Iradimed's insider trading history.
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter.

IRMD Stock News Headlines

Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Iradimed Corp Bottom Line Rises In Q1
Iradimed Announces Quarterly Results
See More Headlines

IRMD Stock Analysis - Frequently Asked Questions

Iradimed's stock was trading at $55.00 on January 1st, 2025. Since then, IRMD shares have increased by 5.7% and is now trading at $58.1150.
View the best growth stocks for 2025 here
.

Iradimed Corporation (NASDAQ:IRMD) issued its earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.05. The medical equipment provider had revenue of $19.39 million for the quarter, compared to the consensus estimate of $19.09 million. Iradimed had a trailing twelve-month return on equity of 24.12% and a net margin of 26.26%.
Read the conference call transcript
.

Iradimed's top institutional investors include Vanguard Group Inc. (4.36%), Copeland Capital Management LLC (3.86%), Goldman Sachs Group Inc. (1.33%) and Acadian Asset Management LLC (1.23%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn.
View institutional ownership trends
.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iradimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/13/2025
Record date for 3/5 Dividend
2/24/2025
Ex-Dividend for 3/5 Dividend
2/24/2025
Dividend Payable
3/05/2025
Record date for 5/30 Dividend
5/20/2025
Ex-Dividend for 5/30 Dividend
5/20/2025
Today
5/30/2025
Dividend Payable
5/30/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:IRMD
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.00
High Stock Price Target
$72.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+25.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
38.40
Forward P/E Ratio
34.70
P/E Growth
N/A
Net Income
$19.23 million
Pretax Margin
33.11%

Debt

Sales & Book Value

Annual Sales
$75.15 million
Cash Flow
$1.44 per share
Price / Cash Flow
40.12
Book Value
$5.66 per share
Price / Book
10.18

Miscellaneous

Free Float
7,971,000
Market Cap
$732.45 million
Optionable
Optionable
Beta
0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:IRMD) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners